These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 8055814)
1. [Response of growth hormone to sandostatin and bromocriptine and prognostic value of prolactin levels in serum and thyroliberin test in patients with active acromegaly]. Gasińska T; Nowak S Endokrynol Pol; 1993; 44(4):455-65. PubMed ID: 8055814 [TBL] [Abstract][Full Text] [Related]
2. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. van der Lely AJ; Harris AG; Lamberts SW Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069 [TBL] [Abstract][Full Text] [Related]
3. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas. Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021 [TBL] [Abstract][Full Text] [Related]
4. Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Yang IM; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK Clin Endocrinol (Oxf); 1995 Mar; 42(3):295-301. PubMed ID: 7758235 [TBL] [Abstract][Full Text] [Related]
6. The value of plasma prolactin levels in the prediction of the responsiveness of growth hormone secretion to bromocriptine and TRH in acromegaly. Lamberts SW; Liuzzi A; Chiodini PG; Verde S; Klijn JG; Birkenhäger JC Eur J Clin Invest; 1982 Apr; 12(2):151-5. PubMed ID: 6807686 [TBL] [Abstract][Full Text] [Related]
7. [The relationship between TSH response to TRH and GH response to dopaminergic agents in patients with acromegaly]. Tokuyama T; Yoshinari M; Okamura K; Ikenoue H; Sato K; Kuroda T; Fujishima M Nihon Naibunpi Gakkai Zasshi; 1991 Feb; 67(2):65-74. PubMed ID: 1674920 [TBL] [Abstract][Full Text] [Related]
8. Effect of bromoergocriptine on TRH-induced growth hormone and prolactin release in acromegalic patients. Ishibashi M; Yamaji T; Kosaka K J Clin Endocrinol Metab; 1977 Aug; 45(2):275-9. PubMed ID: 407240 [TBL] [Abstract][Full Text] [Related]
9. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly. Smals AE; Pieters GF; Smals AG; Hermus AR; Benraad TJ; Kloppenborg PW Clin Endocrinol (Oxf); 1987 Jul; 27(1):43-7. PubMed ID: 3115634 [TBL] [Abstract][Full Text] [Related]
10. Changes in growth hormone (GH) secretion induced by human pancreatic GH releasing hormone-44 in acromegaly: a comparison with thyrotropin-releasing hormone and bromocriptine. Chiodini PG; Liuzzi A; Dallabonzana D; Oppizzi G; Verde GG J Clin Endocrinol Metab; 1985 Jan; 60(1):48-52. PubMed ID: 3917270 [TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339 [TBL] [Abstract][Full Text] [Related]
12. The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ; Liuzzi A Acta Endocrinol (Copenh); 1983 Aug; 103(4):446-50. PubMed ID: 6310918 [TBL] [Abstract][Full Text] [Related]
13. Changes in plasma GH levels and clinical activity during bromocriptine therapy in acromegaly. The value of predictive tests. Nortier JW; Croughs RJ; Donker GH; Thijssen JH; Schwarz F Acta Endocrinol (Copenh); 1984 Jun; 106(2):175-83. PubMed ID: 6145276 [TBL] [Abstract][Full Text] [Related]
14. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. de Herder WW; Taal HR; Uitterlinden P; Feelders RA; Janssen JA; van der Lely AJ Eur J Endocrinol; 2005 Jul; 153(1):67-71. PubMed ID: 15994747 [TBL] [Abstract][Full Text] [Related]
15. Effect of bromocriptine on serum hormones in acromegaly. Carlson HE; Levin SR; Braunstein GD; Spencer EM; Wilson SE; Hershman JM Horm Res; 1984; 19(3):142-52. PubMed ID: 6425186 [TBL] [Abstract][Full Text] [Related]
16. Effects of pirenzepine, bromocriptine and their association on basal and GHRH- and TRH-induced GH secretion in acromegaly. Fiszlejder L; Penacini O; Ratz S; Storani M; Oneto A; Guitelman A Horm Res; 1991; 36(1-2):47-51. PubMed ID: 1814801 [TBL] [Abstract][Full Text] [Related]
17. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly. Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414 [TBL] [Abstract][Full Text] [Related]
18. Bromocriptine therapy in acromegaly: use in patients resistant to conventional therapy and effect on serum levels of somatomedin C. Moses AC; Molitch ME; Sawin CT; Jackson IM; Biller BJ; Furlanetto R; Reichlin S J Clin Endocrinol Metab; 1981 Oct; 53(4):752-8. PubMed ID: 6793607 [TBL] [Abstract][Full Text] [Related]
19. Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly. Ishibashi M; Yamaji T J Clin Endocrinol Metab; 1978 Dec; 47(6):1251-6. PubMed ID: 122426 [TBL] [Abstract][Full Text] [Related]
20. Relationship between somatomedin-C and growth hormone levels in acromegaly: basal and dynamic evaluation. Oppizzi G; Petroncini MM; Dallabonzana D; Cozzi R; Verde G; Chiodini PG; Liuzzi A J Clin Endocrinol Metab; 1986 Dec; 63(6):1348-53. PubMed ID: 2878007 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]